Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...